Eagle IP is excited to sponsor and participate in IAM’s IPBC Connect, returning to Zoom for a week of high-level discussions involving the world’s leading IP experts. From 22-26 March, IAM hosted more than 20 individual interactive digital sessions, each designed to facilitate the exchange of information and insight, benchmarking and the sharing of the best practice in key areas of strategic IP value creation.

Our VP Jennifer Che spoke as an IP expert at an open discussion forum about Patent Law Update Asia, happening March 23 at 11AM HKT (March 22, 11PM EST for those in North America).

You can register for as many sessions as you like across the week, building your own schedule. Find out more here: httpss://cvent.me/VnkWam?RefId=Sponsor

我們過去活動

Recommended Insights

China Releases Draft Examination Guidelines for the new Patent Law

2020年12月4日
The Chinese Patent Office (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but not limited […]

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 1: Delayed Examination

2024年1月25日
December 2023 appears to have been an exceptionally busy and fruitful month in the China patent space. Following the State Council’s approval of the long-awaited Patent Law Implementation Regulations (“Regulations”, similar to the CFR in the US) in November, the CNIPA finally made public the full text of the Regulations just before the arrival of […]

Breaking News: China passes Fourth Amendment to the Chinese Patent Law

2020年10月19日
After 12 years, the Fourth Amendment to the Chinese Patent Law has passed and will be in effect on 1 Jun 2021. After years of multiple draft amendments that moved in various directions, we FINALLY have some clarity on what patent protection is going to look like in China in the coming future. Many of […]

First ever Invalidation decision on an RNAi Invention patent in China

2023年12月4日
Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]
Top crossarrow-right